News Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 11/09/2026 BST			5-day change	1st Jan Change
55.41 ^USD	-0.47%		+0.14%	+25.79%

02:50am	Scholar Rock Receives FDA Approval For ISEMBYLD Apitegromab-Mstn For Treatment Of Spinal Muscular Atrophy	CI
09-11	Scholar Rock gets first FDA nod for rare muscle-wasting disease	RE

All News

Mentions Relevance

02:50am	Scholar Rock Receives FDA Approval For ISEMBYLD Apitegromab-Mstn For Treatment Of Spinal Muscular Atrophy	CI
11:26pm	Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)	BU
09-11	Scholar Rock gets first FDA nod for rare muscle-wasting disease	RE
09-11	US FDA approves Scholar Rock's muscle weakness drug	RE
09-11	Scholar Rock Gets FDA Approval of Isembyld for Spinal Muscular Atrophy	DJ
09-10	Scholar Rock Holding Corporation Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 09:20 AM
09-02	Scholar Rock Receives FDA Fast Track Designation For Apitegromab Facioscapulohumeral Muscular Dystrophy Program As Participant Dosing Commences In Phase 2 FORGE Trial	CI
09-02	Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug	MT
09-02	Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial	BU
08-27	Scholar Rock to Present at Upcoming Investor Conferences	BU
08-21	Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says	MT
08-21	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT
08-21	Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission	RE
08-21	Scholar Rock Announces Removal Of Catalent Indiana As Fill-Finish Facility And Progresses Apitegromab Regulatory Filings With FDA, EMA, And PMDA	CI
08-21	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan	CI
08-21	Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility	MT
08-21	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan	BU
08-14	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
08-10	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-07	Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug	RE
08-07	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag	DJ
08-07	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-07	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date	BU
08-06	Scholar Rock Holding Corporation, Q2 2026 Earnings Call, Aug 06, 2026
08-06	Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI